Obermüller Dominik, Jerosch Jörg, Bovy Leonore, Häckl Dennis, Ivanavicius Stefan, Liedgens Hiltrud
InGef - Institute for Applied Health Research Berlin GmbH, Otto-Ostrowski-Str. 5, 10249 Berlin, Germany.
Medizinisches Wissenschafts- und Gutachten-Institut Meerbusch, Grabenstr. 11, 40667 Meerbusch, Germany.
Osteoarthr Cartil Open. 2023 Dec 21;6(1):100430. doi: 10.1016/j.ocarto.2023.100430. eCollection 2024 Mar.
Osteoarthritis of the knee (knee OA) is a serious joint disease leading to pain and reduced quality of life. Pharmacological treatments include anti-inflammatories, analgesics, intraarticular hyaluronic acid, and intraarticular corticosteroids while for severe knee OA, knee replacement is an option. This study examined the incidence, prevalence, patient characteristics, and uptake of medical and surgical treatments in knee OA patients in Germany.
A non-interventional, retrospective health claims data analysis with anonymized data from the InGef database was performed. Patients ≥18 years were analyzed cross-sectionally for each year 2015-2020. Newly diagnosed patients in 2015 were also longitudinally analyzed until end of 2020.
Annual knee OA prevalence increased from 7.07 % in 2015 to 7.39 % in 2020. Annual incidence proportions ranged from 1.71 % in 2015 to 1.46 % in 2020. Knee replacement was the most common surgery, with rising patient numbers (e.g., 7918 patients in 2015 and 8975 patients in 2019). Approximately 62 % of patients newly diagnosed in 2015 received prescription pharmacological pain treatment during follow-up. Most (96.95 %) received non-opioid analgesics, followed by weak opioids (8.14 %) and strong opioids (3.00 %) as first-line treatment (combinations possible). Knee surgery was performed in 16.6 % of patients during follow-up. Median time from first diagnosis until surgery was 346 days for any knee surgery and 564 days for knee replacement.
The number of patients with knee OA in Germany is steadily rising, along with an increasing number of surgical interventions, especially knee replacement. Time until first surgery and knee replacement is relatively short, even for newly diagnosed patients.
膝关节骨关节炎（膝骨关节炎）是一种严重的关节疾病，会导致疼痛并降低生活质量。药物治疗包括抗炎药、镇痛药、关节腔内注射透明质酸和关节腔内注射皮质类固醇，而对于严重的膝骨关节炎，膝关节置换是一种选择。本研究调查了德国膝骨关节炎患者的发病率、患病率、患者特征以及药物和手术治疗的采用情况。
利用InGef数据库中的匿名数据进行了一项非干预性回顾性健康索赔数据分析。对2015 - 2020年每年年龄≥18岁的患者进行横断面分析。对2015年新诊断的患者也进行了直至2020年底的纵向分析。
膝骨关节炎的年患病率从2015年的7.07%升至2020年的7.39%。年发病率比例从2015年的1.71%至2020年的1.46%不等。膝关节置换是最常见的手术，患者数量不断增加（例如，2015年有7918例患者，2019年有8975例患者）。2015年新诊断的患者中约62%在随访期间接受了处方药物止痛治疗。大多数（96.95%）接受非阿片类镇痛药，其次是弱阿片类药物（8.14%）和强阿片类药物（3.00%）作为一线治疗（可能存在联合用药）。随访期间16.6%的患者接受了膝关节手术。从首次诊断到进行任何膝关节手术的中位时间为346天，膝关节置换为564天。
德国膝骨关节炎患者数量在稳步上升，手术干预数量也在增加，尤其是膝关节置换。即使对于新诊断的患者，首次手术和膝关节置换的时间也相对较短。
